MA43106B1 - Traitement de l'oligo-ovulation associée à la stéatose hepatique - Google Patents

Traitement de l'oligo-ovulation associée à la stéatose hepatique

Info

Publication number
MA43106B1
MA43106B1 MA43106A MA43106A MA43106B1 MA 43106 B1 MA43106 B1 MA 43106B1 MA 43106 A MA43106 A MA 43106A MA 43106 A MA43106 A MA 43106A MA 43106 B1 MA43106 B1 MA 43106B1
Authority
MA
Morocco
Prior art keywords
oligo
treatment
hepatic steatosis
ovulation
composition
Prior art date
Application number
MA43106A
Other languages
English (en)
Other versions
MA43106A (fr
Inventor
Lourdes Ibáñez
Zegher Francis De
Original Assignee
Univ Leuven Kath
Sant Joan De Deu Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leuven Kath, Sant Joan De Deu Hospital filed Critical Univ Leuven Kath
Publication of MA43106A publication Critical patent/MA43106A/fr
Publication of MA43106B1 publication Critical patent/MA43106B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une méthode et une composition à utiliser pour traiter un état pathologique qui bénéficie de la réduction de graisse viscérale et/ou hépatique, notamment le syndrome des ovaires polykystiques chez les adolescentes ou les femmes en âge de procréer, la méthode et la composition impliquant l'utilisation de spironolactone, de pioglitazone et de metformine.
MA43106A 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique MA43106B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1518979.8A GB201518979D0 (en) 2015-10-27 2015-10-27 Treatment of hepatic steatosis related oligo-ovulation
PCT/EP2016/075953 WO2017072243A1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hépatique

Publications (2)

Publication Number Publication Date
MA43106A MA43106A (fr) 2021-05-05
MA43106B1 true MA43106B1 (fr) 2021-09-30

Family

ID=55130283

Family Applications (2)

Application Number Title Priority Date Filing Date
MA054412A MA54412A (fr) 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale
MA43106A MA43106B1 (fr) 2015-10-27 2016-10-27 Traitement de l'oligo-ovulation associée à la stéatose hepatique

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA054412A MA54412A (fr) 2015-10-27 2016-10-27 Traitement d'excès de graisse hépatique et/ou viscérale

Country Status (24)

Country Link
US (2) US20190060328A1 (fr)
EP (2) EP3892281A3 (fr)
JP (2) JP6999903B2 (fr)
KR (1) KR102608158B1 (fr)
CN (2) CN108778285A (fr)
AR (1) AR106505A1 (fr)
AU (1) AU2016344737C1 (fr)
BR (1) BR112018008496A2 (fr)
CA (1) CA3003076C (fr)
DK (1) DK3368044T3 (fr)
ES (1) ES2883282T3 (fr)
GB (1) GB201518979D0 (fr)
HU (1) HUE055778T2 (fr)
IL (1) IL258876B (fr)
LT (1) LT3368044T (fr)
MA (2) MA54412A (fr)
MX (2) MX2018005252A (fr)
PL (1) PL3368044T3 (fr)
RS (1) RS62764B1 (fr)
RU (1) RU2745606C2 (fr)
SI (1) SI3368044T1 (fr)
TW (1) TWI791420B (fr)
UY (1) UY36967A (fr)
WO (1) WO2017072243A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202005618WA (en) 2017-12-19 2020-07-29 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
CA3107945A1 (fr) * 2018-08-02 2020-02-06 Hospital Sant Joan De Deu Formulation a liberation immediate d'une triple combinaison d'ingredients pharmaceutiques actifs utile dans le traitement du syndrome des ovaires polykystiques
EP3842803A1 (fr) * 2019-12-23 2021-06-30 Katholieke Universiteit Leuven Cxcl14 dans le syndrome des ovaires polykystiques
KR20230041965A (ko) 2020-05-13 2023-03-27 아카우오스, 인크. Slc26a4-연관 청력손실을 치료하기 위한 조성물 및 방법
MX2023006451A (es) 2020-12-01 2023-06-15 Akouos Inc Construcciones de anticuerpos anti-vegf y metodos relacionados para el tratamiento de los sintomas asociados al schwannoma vestibular.
EP4271419A1 (fr) 2020-12-29 2023-11-08 Akouos, Inc. Compositions et méthodes pour traiter une perte auditive et/ou une perte de la vision associées à clrn1
TW202342525A (zh) 2022-02-02 2023-11-01 美商阿科奧斯公司 用於治療前庭神經鞘瘤相關症狀之抗ｖｅｇｆ抗體構築體及相關方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478852C1 (en) * 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US6046222A (en) * 1993-09-15 2000-04-04 Warner-Lambert Company Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
ATE359065T1 (de) * 2000-02-23 2007-05-15 Orentreich Foundation For The Verwendung von einem insulin-sensibilisator in der behandlung von alopecia
GB0106565D0 (en) * 2001-03-16 2001-05-09 Leuven K U Res & Dev Growth hormone treatment
GB0108863D0 (en) * 2001-04-10 2001-05-30 Leuven K U Res & Dev Combinational therapy
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
AU2003256988A1 (en) * 2002-12-11 2004-06-30 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
GB0702537D0 (en) * 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US10474539B1 (en) * 2015-12-18 2019-11-12 EMC IP Holding Company LLC Browsing federated backups
CA3107945A1 (fr) * 2018-08-02 2020-02-06 Hospital Sant Joan De Deu Formulation a liberation immediate d'une triple combinaison d'ingredients pharmaceutiques actifs utile dans le traitement du syndrome des ovaires polykystiques

Also Published As

Publication number Publication date
RU2018119146A3 (fr) 2020-02-25
CN117379440A (zh) 2024-01-12
ES2883282T3 (es) 2021-12-07
MX2018005252A (es) 2018-09-18
PL3368044T3 (pl) 2021-12-20
MX2021007976A (es) 2021-08-16
UY36967A (es) 2017-05-31
AU2016344737C1 (en) 2021-10-07
AU2016344737B2 (en) 2021-07-08
GB201518979D0 (en) 2015-12-09
LT3368044T (lt) 2021-10-25
US20240000804A1 (en) 2024-01-04
TWI791420B (zh) 2023-02-11
EP3892281A2 (fr) 2021-10-13
RU2018119146A (ru) 2019-11-28
KR20180098234A (ko) 2018-09-03
EP3892281A3 (fr) 2021-11-10
WO2017072243A9 (fr) 2018-07-26
CA3003076A1 (fr) 2017-05-04
EP3368044B1 (fr) 2021-06-09
IL258876B (en) 2022-03-01
WO2017072243A8 (fr) 2018-03-22
WO2017072243A1 (fr) 2017-05-04
KR102608158B1 (ko) 2023-11-29
JP2019501113A (ja) 2019-01-17
AR106505A1 (es) 2018-01-24
SI3368044T1 (sl) 2022-05-31
MA54412A (fr) 2021-11-10
EP3368044A1 (fr) 2018-09-05
RS62764B1 (sr) 2022-01-31
CN108778285A (zh) 2018-11-09
CA3003076C (fr) 2023-12-05
BR112018008496A2 (pt) 2018-10-23
IL258876A (en) 2018-06-28
JP6999903B2 (ja) 2022-02-04
RU2745606C2 (ru) 2021-03-29
AU2016344737A9 (en) 2018-08-09
TW201720432A (zh) 2017-06-16
DK3368044T3 (da) 2021-09-13
MA43106A (fr) 2021-05-05
HUE055778T2 (hu) 2021-12-28
JP2022009374A (ja) 2022-01-14
US20190060328A1 (en) 2019-02-28
AU2016344737A1 (en) 2018-05-17

Similar Documents

Publication Publication Date Title
MA43106B1 (fr) Traitement de l'oligo-ovulation associée à la stéatose hepatique
MA45819A (fr) Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
JO3558B1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
PH12018500016A1 (en) Agents, uses and methods for the treatment of synucleinopathy
MA42560B1 (fr) Compositions comprenant des souches bactériennes de blautia pour le traitement de l'hypersensibilité viscérale
MA46836A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MX2022011002A (es) Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos.
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
EA036102B9 (ru) Терапевтические средства с углевод-опосредованной адресной доставкой
MY181888A (en) Tmprss6 irna compositions and methods of use thereof
PH12018500578A1 (en) Methods of treating inflammatory diseases
MX2018009325A (es) Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn).
MA53329A (fr) Méthodes de traitement de l'épilepsie
PT3597816T (pt) Composições de banho de imersão para o tratamento de insertos de reforço
MA46459B1 (fr) Méthode de traitement de lésions rénales aiguës
EA201890861A1 (ru) Композиции, содержащие лентивирусные векторы, экспрессирующие il-12, и способы их применения
MX2017012610A (es) Composiciones y metodos para inhibir la expresion del gen lect2.
PL3597686T3 (pl) Kompozycja kąpieli zanurzeniowej do obróbki wkładek wzmacniających
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MA43848A (fr) Composés deutérés pour le traitement d'hémopathies malignes, compositions et procédés associés
MX2017004842A (es) Levosimendan para uso en el tratamiento de enfermedades de las neuronas motoras (por ejemplo esclerosis lateral amiotrofica).
MA55218A (fr) Eskétamine pour le traitement de la dépression
MA48791A (fr) Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies
FR3032616B1 (fr) Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites
GB2567398A (en) Method and composition for treating dysbiosis and related disease states